• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpenoids
• Triterpenoids

Ganoderic acid ε (CAS No. 294674-05-8): A Comprehensive Overview of Its Bioactive Properties and Recent Research Findings

Ganoderic acid ε, identified by its chemical abstracts service number CAS No. 294674-05-8, is a significant triterpenoid compound derived from the medicinal mushroom *Ganoderma lucidum*. This compound has garnered considerable attention in the field of pharmaceutical research due to its diverse biological activities and potential therapeutic applications. Ganoderic acid ε belongs to the lanostane class of triterpenes, which are known for their structural complexity and wide-ranging pharmacological effects.

The chemical structure of Ganoderic acid ε features multiple functional groups, including hydroxyl and ketone moieties, which contribute to its unique interactions with biological targets. These structural characteristics have been extensively studied, revealing mechanisms by which it exerts its pharmacological effects. The compound's molecular framework allows it to modulate various cellular pathways, making it a promising candidate for the development of novel therapeutic agents.

Recent research has highlighted the anti-inflammatory properties of Ganoderic acid ε. Studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). These findings suggest that Ganoderic acid ε may be effective in managing chronic inflammatory conditions by suppressing inflammatory responses at both the molecular and cellular levels.

In addition to its anti-inflammatory effects, Ganoderic acid ε has shown significant potential in antioxidant therapy. Oxidative stress is a key factor in the pathogenesis of numerous diseases, including neurodegenerative disorders, cardiovascular diseases, and cancer. Preclinical studies have indicated that Ganoderic acid ε can scavenge reactive oxygen species (ROS) and enhance the activity of endogenous antioxidant enzymes. This protective effect against oxidative damage may contribute to its therapeutic benefits in various pathological conditions.

The role of Ganoderic acid ε in immune modulation has also been extensively investigated. Research suggests that this compound can enhance immune function by activating macrophages and natural killer (NK) cells. Furthermore, Ganoderic acid ε has been shown to modulate T-cell subsets, promoting a balanced immune response. These immunomodulatory effects make it a valuable candidate for therapeutic strategies aimed at enhancing host defense mechanisms.

Emerging evidence also indicates that Ganoderic acid ε possesses anticancer properties. Studies have demonstrated its ability to induce apoptosis in various cancer cell lines by inhibiting key signaling pathways involved in cell survival and proliferation. For instance, Ganoderic acid ε has been shown to downregulate the expression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL while upregulating pro-apoptotic proteins like Bax and caspase-3. These findings suggest that Ganoderic acid ε may serve as a potent chemopreventive or chemotherapeutic agent in cancer treatment.

The neuroprotective effects of Ganoderic acid ε have garnered significant interest in recent years. Preclinical studies have revealed that this compound can protect against neurotoxicity induced by oxidative stress and excitotoxicity. Additionally, Ganoderic acid ε has been shown to improve cognitive function in animal models of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. These findings highlight the potential of Ganoderic acid ε as a therapeutic agent for neuroprotective applications.

The pharmacokinetic profile of Ganoderic acid ε is another area of active research. Studies have examined its absorption, distribution, metabolism, and excretion (ADME) properties to better understand its bioavailability and potential interactions with other drugs. While further research is needed to fully elucidate its pharmacokinetic characteristics, initial findings suggest that Ganoderic acid ε exhibits moderate bioavailability and undergoes metabolic transformation primarily via cytochrome P450 enzymes.

The synthetic pathways for producing high-purity Ganoderic acid ε are also being explored to meet the growing demand for this compound in pharmaceutical applications. Researchers are investigating both fermentation-based methods using *Ganoderma lucidum* mycelia and chemical synthesis routes to optimize yield and purity. These efforts aim to make Ganoderic acid ε more accessible for clinical trials and commercialization.

In conclusion, Ganoderic acid ε (CAS No. 294674-05-8) is a multifaceted bioactive compound with significant therapeutic potential across various medical conditions. Its anti-inflammatory, antioxidant, immunomodulatory, anticancer, and neuroprotective properties make it a promising candidate for future drug development. Ongoing research continues to uncover new insights into its mechanisms of action and pharmacological effects, paving the way for innovative therapeutic strategies in the field of medicinal chemistry.

• 150033-91-3(Lanosta-8,24-dien-26-oic acid, 3,20-dihydroxy-7,11,15-trioxo-, (3β,20ξ,24E)- (9CI))
• 110241-25-3(Chol-8-en-24-oic acid,3,7-dihydroxy-4-(hydroxymethyl)-4,14-dimethyl-11,15-dioxo-, (3b,4a,5a,7b)-)
• 81907-61-1(Ganoderic acid B)
• 100665-41-6(Ganoderenic acid B)
• 163565-76-2(Ergosta-8,24(28)-dien-26-oicacid, 7-hydroxy-4-methyl-3,11-dioxo-, (4a,5a,7b,25S)-)
• 100665-43-8(Ganoderenic acid D)
• 217476-76-1((3beta,24E)-3-hydroxy-11,15-dioxolanosta-8,24-dien-26-oic acid)
• 102607-22-7((24E)-15α,23-Dihydroxy-3,11-dioxo-5α-lanosta-8,24-dien-26-oic acid)
• 95311-97-0(Ganoderic acid C1)
• 108340-60-9(Ganoderic acid D)